|This is a Phase 1 dose-finding study of FT536 monotherapy and in combination with monoclonal antibodies.
|This is a Phase 1 dose-finding study of FT536 given in combination with a monoclonal antibody following lymphodepletion in subjects with advanced solid tumors. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
|Clinical trials phase
|Start date (estimated)
|End date (estimated)
|Advanced Malignant Solid Neoplasm
|A malignant solid neoplasm that has spread extensively to other anatomic sites or is no longer responding to treatment.
|Other study identifiers
|Which differentiated cell type is used
|natural killer cell
|A lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation via germline encoded activation receptors and also regulate immune responses via cytokine release and direct contact with other cells.
|Estimated number of participants